Tyligand Bioscience and Context Therapeutics Sign Strategic Development Agreement for Onapristone ER

2020-03-13

Tyligand Bioscience and Phildelphia based biotech Context Therapeutics announced the signing of collaboration agreements for the development, manufacturing, registration and future commercialization of onapristone extended release (ER).